Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MG
MCID: MYS003
MIFTS: 68

Myasthenia Gravis (MG)

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Myasthenia Gravis

About this section

MalaCards integrated aliases for Myasthenia Gravis:

Name: Myasthenia Gravis 56 12 74 52 25 53 58 36 29 54 42 43 15 37 17 71 32
Mg 56 25
Autoimmune Myasthenia Gravis 58
Acquired Myasthenia 58

Characteristics:

Orphanet epidemiological data:

58
myasthenia gravis
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe),1-5/10000 (Europe),1-9/100000 (Worldwide),1-9/1000000 (United States),1-5/10000 (Canada),1-9/100000 (Spain),1-5/10000 (United Kingdom),1-9/100000 (United Kingdom),1-9/100000 (Serbia),1-5/10000 (United States),1-5/10000 (Serbia),1-9/100000 (Italy),1-5/10000 (Austria),1-9/100000 (Australia),1-5/10000 (Italy),1-9/100000 (Taiwan, Province of China),1-5/10000 (Australia),1-9/1000000 (Greece),1-5/10000 (Taiwan, Province of China),1-9/1000000 (Croatia),1-9/100000 (Estonia),1-9/100000 (Greece),1-9/100000 (Croatia),1-9/100000 (Egypt),1-9/1000000 (Worldwide); Age of onset: All ages; Age of death: normal life expectancy;

OMIM:

56
Inheritance:
usually sporadic
1 to 4 % of cases are familial without a simple mendelian pattern
familial predisposition may be due to autoimmunity in general.


HPO:

31
myasthenia gravis:
Inheritance multifactorial inheritance


Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases Eye diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare neurological diseases
Rare eye diseases


Sources

Summaries for Myasthenia Gravis

About this section
Genetics Home Reference : 25 Myasthenia gravis is a disorder that causes weakness of the skeletal muscles, which are muscles that the body uses for movement. The weakness most often starts in the muscles around the eyes, causing drooping of the eyelids (ptosis) and difficulty coordinating eye movements, which results in blurred or double vision. In a form of the disorder called ocular myasthenia, the weakness remains confined to the eye muscles. In most people with myasthenia gravis, however, additional muscles in the face and neck are affected. Affected individuals may have unusual facial expressions, difficulty holding up the head, speech impairment (dysarthria), and chewing and swallowing problems (dysphagia) that may lead to choking, gagging, or drooling. Other muscles in the body are also affected in some people with myasthenia gravis. The muscles of the arms and legs may be involved, causing affected individuals to have changes in their gait or trouble with lifting objects, rising from a seated position, or climbing stairs. The muscle weakness tends to fluctuate over time; it typically worsens with activity and improves with rest. Weakness of the muscles in the chest wall and the muscle that separates the abdomen from the chest cavity (the diaphragm) can cause breathing problems in some people with myasthenia gravis. About 10 percent of people with this disorder experience a potentially life-threatening complication in which these respiratory muscles weaken to the point that breathing is dangerously impaired, and the affected individual requires ventilation assistance. This respiratory failure, called a myasthenic crisis, may be triggered by stresses such as infections or reactions to medications. People can develop myasthenia gravis at any age. For reasons that are unknown, it is most commonly diagnosed in women younger than age 40 and men older than age 60. It is uncommon in children, but some infants born to women with myasthenia gravis show signs and symptoms of the disorder for the first few days or weeks of life. This temporary occurrence of symptoms is called transient neonatal myasthenia gravis.

MalaCards based summary : Myasthenia Gravis, also known as mg, is related to neonatal myasthenia gravis and congenital myasthenic syndrome, and has symptoms including muscle weakness, dysphagia and dyspnea. An important gene associated with Myasthenia Gravis is AKAP12 (A-Kinase Anchoring Protein 12), and among its related pathways/superpathways are Allograft rejection and Immune response NFAT in immune response. The drugs Azathioprine and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include thymus, t cells and testes, and related phenotypes are dysphagia and dyspnea

Disease Ontology : 12 An autoimmune disease of the nervous system that has material basis in antibodies to acetylcholine receptors at the neuromuscular junction, has symptom ptosis, has symptom diplopia, has symptom dysphagia, has symptom dysarthria, has symptom muscle weakness and has symptom dyspnea.

NIH Rare Diseases : 52 Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles. Common symptoms include weakness of the muscles that control the eye and eyelid, facial expressions, chewing, talking, and swallowing. Weakness tends to increase during periods of activity and improve after periods of rest. The condition results from a defect in the transmission of nerve impulses to muscles, which is due to the presence of antibodies against acetylcholine . The exact reason this occurs is not known. Some cases have been linked to tumors in the thymus gland . Researchers believe that variations in certain genes may increase a person's risk to develop MG, but other factors likely also play a role. There is no cure for MG at this time, but treatment can significantly improve muscle weakness. Some cases may go into remission temporarily, and muscle weakness may disappear so that medications can be discontinued.

MedlinePlus : 42 Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest. Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker. Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps. Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent. NIH: National Institute of Neurological Disorders and Stroke

NINDS : 53 Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal muscles of the body, which are responsble for breathing and moving parts of the body, including the arms and legs. In myasthenia gravis, the immune system--which normally protects the body from foreign organisms--mistakenly attacks itself.   Symptoms vary in type and intensity, and may include: • muscle weakness in the arms, hands, fingers, legs and neck • weakness of the eye muscles • drooping eyelid • difficulty swallowing • shortness of breath • impaired speaking Myasthenia gravis is caused by an error in the transmission of nerve impulses to muscles. Antibodies (immune proteins produced by the body's immune system) block the normal activity of the neurotransmitter acetylcholine, which prevents muscles from contracting. The thymus gland also may give incorrect instructions to immune cells and cause the immune system to attack its own cells and tissues. .

KEGG : 36 Myasthenia gravis (MG) is an autoimmune disorder characterized by a defective transmission of nerve impulses to muscles leading to muscle weakness and fatigability. Some, but not all, muscles are affected and not necessarily symmetrically. Increased weakness with continued muscle activity represents a diagnostic clue for MG, but these clinical features can vary. MG is B-cell mediated, and is associated with antibodies directed against the acetylcholine receptor (AChR), muscle-specific kinase (MUSK), lipoprotein-related protein 4 (LRP4), or agrin in the postsynaptic membrane at the neuromuscular junction. Patients should be classified into subgroups to help with therapeutic decisions and prognosis. Subgroups based on serum antibodies and clinical features include early-onset, late-onset, thymoma, MUSK, LRP4, antibody-negative, and ocular forms of myasthenia gravis. Agrin-associated MG might emerge as a new entity. The prognosis is good with optimum symptomatic, immunosuppressive, and supportive treatment. The evolution of MG is unpredictable, but it is generally characterized by the occurrence of relapses, sometimes subsequent to remissions and a worsening trend. For 85% of MG patients, the maximum severity is reached within less than 3 years.

Wikipedia : 74 Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal... more...

More information from OMIM: 254200
Sources

Related Diseases for Myasthenia Gravis

About this section

Diseases in the Myasthenia Gravis family:

Juvenile Myasthenia Gravis Adult-Onset Myasthenia Gravis

Diseases related to Myasthenia Gravis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1106)
# Related Disease Score Top Affiliating Genes
1 neonatal myasthenia gravis 34.9 MUSK CHRNG AGRN
2 congenital myasthenic syndrome 33.3 TTN RYR1 RAPSN MUSK CHRNG CHRNE
3 neuromyelitis optica 33.1 TNFSF13B MBP IL4
4 thymoma 33.1 TTN TNF RYR1 IL4 IL2 CTLA4
5 thymus cancer 33.1 TTN MUSK IL2 CTLA4 AIRE AGRN
6 multiple pterygium syndrome, escobar variant 32.9 RYR1 RAPSN CHRNG CHRNA1
7 neuromuscular disease 32.6 TTN TMPO RYR1 RAPSN MUSK CHRNG
8 neuromuscular junction disease 32.2 RAPSN MUSK CHRNG CHRNE CHRNA1 AGRN
9 lambert-eaton myasthenic syndrome 32.0 TTN TNF MUSK IL10
10 respiratory failure 31.9 TTN TNF RYR1 MUSK IL10 ACHE
11 myositis 31.8 TTN TNF RYR1 IFNG
12 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.7 TNFSF13B IL10 IFNG CTLA4 AIRE
13 thyroiditis 31.7 TNF IL4 IL2 IL10 CTLA4
14 ptosis 31.7 TTN RYR1 RAPSN MUSK CHRNG CHRNE
15 graft-versus-host disease 31.4 TNF IL2 IL10 IFNG
16 myelitis 31.4 TNF MBP IL10
17 myocarditis 31.4 TNF IL4 IL2 IL10 IFNG CTLA4
18 chronic graft versus host disease 31.4 TNFSF13B IL10 IFNG
19 graves' disease 31.3 IL4 IFNG CTLA4 AIRE
20 transverse myelitis 31.3 TNF MBP IL10
21 chronic inflammatory demyelinating polyradiculoneuropathy 31.3 MBP IL10 IFNG
22 myopathy 31.3 TTN TNFSF13B RYR1 RAPSN IL4 IFNG
23 postsynaptic congenital myasthenic syndromes 31.3 RAPSN MUSK CHRNE CHRNA1 AGRN
24 anemia, autoimmune hemolytic 31.2 TNFSF13B IL2 CTLA4
25 autoimmune disease 31.2 TNFSF13B TNF MUSK MBP IL4 IL2
26 optic neuritis 31.2 TNF MBP IL10
27 purpura 31.2 TNFSF13B TNF IL4 IL10 IFNG
28 cholangitis 31.1 TNF IL2 IL10 CTLA4
29 systemic scleroderma 31.1 TNF IL4 IL10 IFNG
30 neuritis 31.1 TNF MBP IL4 IL10 IFNG
31 ulcerative colitis 31.1 TNF IL4 IL2 IL10 IFNG
32 allergic hypersensitivity disease 31.1 TNF IL4 IL2 IL10 IFNG
33 vitiligo-associated multiple autoimmune disease susceptibility 1 31.0 IL2 CTLA4 AIRE
34 lichen planus 31.0 TNF IL4 IL2 IL10 IFNG
35 exanthem 31.0 TNF IL2 IL10 IFNG CTLA4
36 vasculitis 31.0 TNFSF13B TNF IL10 CTLA4
37 hemolytic anemia 31.0 TNF IL4 IL2 IL10 IFNG
38 aseptic meningitis 31.0 TNF IL10 IFNG
39 spondylitis 31.0 TNF IL10 IFNG
40 polyradiculoneuropathy 31.0 MBP IL10 IFNG
41 meningitis 31.0 TNF IL4 IL2 IL10 IFNG
42 diphtheria 31.0 TNF IL4 IL2 IFNG
43 lymphadenitis 30.9 TNF IL10 IFNG
44 alopecia 30.9 TNF IL4 IL2 IFNG CTLA4 AIRE
45 lymphopenia 30.9 IL4 IL2 IL10 IFNG CTLA4
46 autoimmune myocarditis 30.9 TNF IFNG
47 colitis 30.9 TNF IL4 IL2 IL10 IFNG CTLA4
48 pemphigus 30.9 TNF IL4 IL10
49 castleman disease 30.9 IL4 IL10 IFNG
50 aplastic anemia 30.8 TNF IL4 IL2 IL10 IFNG CTLA4

Graphical network of the top 20 diseases related to Myasthenia Gravis:



Diseases related to Myasthenia Gravis
Sources

Symptoms & Phenotypes for Myasthenia Gravis

About this section

Human phenotypes related to Myasthenia Gravis:

58 31 (show all 40)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dysphagia 58 31 frequent (33%) Frequent (79-30%) HP:0002015
2 dyspnea 58 31 frequent (33%) Frequent (79-30%) HP:0002094
3 myositis 58 31 frequent (33%) Frequent (79-30%) HP:0100614
4 ptosis 58 31 frequent (33%) Frequent (79-30%) HP:0000508
5 dysarthria 58 31 frequent (33%) Frequent (79-30%) HP:0001260
6 ophthalmoparesis 58 31 frequent (33%) Frequent (79-30%) HP:0000597
7 diplopia 58 31 frequent (33%) Frequent (79-30%) HP:0000651
8 bulbar palsy 58 31 frequent (33%) Frequent (79-30%) HP:0001283
9 abnormality of the thymus 58 31 frequent (33%) Frequent (79-30%) HP:0000777
10 single fiber emg abnormality 58 31 frequent (33%) Frequent (79-30%) HP:0030006
11 acetylcholine receptor antibody positivity 58 31 frequent (33%) Frequent (79-30%) HP:0030208
12 muscle specific kinase antibody positivity 58 31 frequent (33%) Frequent (79-30%) HP:0030210
13 hearing impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0000365
14 hashimoto thyroiditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000872
15 paresthesia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003401
16 hyperthyroidism 58 31 occasional (7.5%) Occasional (29-5%) HP:0000836
17 hyperacusis 58 31 occasional (7.5%) Occasional (29-5%) HP:0010780
18 primary adrenal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0008207
19 raynaud phenomenon 58 31 occasional (7.5%) Occasional (29-5%) HP:0030880
20 glycosuria 58 31 occasional (7.5%) Occasional (29-5%) HP:0003076
21 rheumatoid arthritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001370
22 systemic lupus erythematosus 58 31 occasional (7.5%) Occasional (29-5%) HP:0002725
23 acrocyanosis 58 31 very rare (1%) Very rare (<4-1%) HP:0001063
24 hepatitis 58 31 very rare (1%) Very rare (<4-1%) HP:0012115
25 hemolytic anemia 58 31 very rare (1%) Very rare (<4-1%) HP:0001878
26 psychosis 58 31 very rare (1%) Very rare (<4-1%) HP:0000709
27 pure red cell aplasia 58 31 very rare (1%) Very rare (<4-1%) HP:0012410
28 seizure 31 very rare (1%) HP:0001250
29 seizures 58 Very rare (<4-1%)
30 muscle weakness 58 Very frequent (99-80%)
31 autoimmunity 31 HP:0002960
32 abnormality of the immune system 31 HP:0002715
33 facial palsy 31 HP:0010628
34 nasal speech 31 HP:0001611
35 abnormality of the endocrine system 31 HP:0000818
36 proximal muscle weakness 31 HP:0003701
37 impaired mastication 31 HP:0005216
38 fatigable weakness 31 HP:0003473
39 thymoma 31 HP:0100522
40 limb muscle weakness 31 HP:0003690

Symptoms via clinical synopsis from OMIM:

56
G I:
dysphagia

H E E N T:
ptosis
dysarthria
diplopia
facial muscle weakness
difficulty chewing

Muscle:
proximal limb muscle weakness.

Pulmonary:
ventilatory insufficiency

Immunology:
autoimmunity
thymoma
antibodies to acetylcholine receptor (achr)
association with gm type

Voice:
nasal speech

Endocrine:
thyrotoxicosis

Misc:
childhood or adolescent onset
static or only slowly progressive

Clinical features from OMIM:

254200

Symptoms:

12
  • • muscle weakness
  • • dysphagia
  • • dyspnea
  • • ptosis
  • • dysarthria
  • • diplopia

UMLS symptoms related to Myasthenia Gravis:


seizures, muscle weakness, tremor, back pain, headache, syncope, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness, facial paresis

GenomeRNAi Phenotypes related to Myasthenia Gravis according to GeneCards Suite gene sharing:

26 (show all 38)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-107 9.96 ACHE
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-126 9.96 MUSK
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-128 9.96 IL10
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-132 9.96 IL10
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-161 9.96 AIRE
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.96 IL10
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.96 IL10
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-194 9.96 TNFSF13B
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 9.96 AIRE
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.96 TNFSF13B
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-25 9.96 IL10
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-32 9.96 MUSK
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.96 IL10
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-39 9.96 TNFSF13B
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 9.96 AIRE
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.96 ACHE
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 9.96 MUSK
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-8 9.96 TNFSF13B
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-80 9.96 IL10
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-85 9.96 AIRE
21 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.6 TMPO
22 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.6 RAPSN
23 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.6 CHRNA1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.6 TMPO
25 Increased shRNA abundance (Z-score > 2) GR00366-A-141 9.6 TMPO
26 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.6 TMPO
27 Increased shRNA abundance (Z-score > 2) GR00366-A-155 9.6 CHRNA1 RAPSN
28 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.6 TMPO
29 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.6 CHRNA1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.6 TMPO
31 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.6 RAPSN
32 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.6 CHRNA1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.6 CHRNA1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.6 CHRNA1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.6 CHRNA1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.6 CHRNA1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.6 CHRNA1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.6 RAPSN

MGI Mouse Phenotypes related to Myasthenia Gravis:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.44 ACHE AGRN AIRE AKAP12 CHRNA1 CHRNE
2 growth/size/body region MP:0005378 10.37 ACHE AGRN AIRE CHRNE CHRNG IFNG
3 homeostasis/metabolism MP:0005376 10.37 ACHE AGRN AIRE CHRNG CTLA4 IFNG
4 hematopoietic system MP:0005397 10.36 ACHE AIRE AKAP12 CTLA4 IFNG IL10
5 mortality/aging MP:0010768 10.36 ACHE AGRN AIRE AKAP12 CHRNA1 CHRNE
6 immune system MP:0005387 10.29 AIRE AKAP12 CTLA4 IFNG IL10 IL2
7 digestive/alimentary MP:0005381 10.2 AIRE CTLA4 IFNG IL10 IL2 IL4
8 endocrine/exocrine gland MP:0005379 10.19 AIRE AKAP12 CTLA4 IFNG IL10 IL2
9 nervous system MP:0003631 10.17 ACHE AGRN AIRE AKAP12 CHRNA1 CHRNE
10 muscle MP:0005369 10.15 ACHE AGRN AKAP12 CHRNE CHRNG IFNG
11 integument MP:0010771 10.11 CHRNG CTLA4 IFNG IL10 IL4 MUSK
12 craniofacial MP:0005382 10.1 ACHE IFNG IL10 IL4 RYR1 TNF
13 liver/biliary system MP:0005370 10.03 AIRE AKAP12 CTLA4 IFNG IL10 IL2
14 no phenotypic analysis MP:0003012 9.86 ACHE AIRE CHRNE IFNG IL10 IL2
15 respiratory system MP:0005388 9.83 ACHE AGRN AIRE AKAP12 CHRNE CHRNG
16 normal MP:0002873 9.81 AGRN AIRE AKAP12 CTLA4 IFNG IL10
17 vision/eye MP:0005391 9.28 ACHE AIRE IFNG IL10 IL2 IL4
Sources

Drugs & Therapeutics for Myasthenia Gravis

About this section

Drugs for Myasthenia Gravis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 172)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4 446-86-6 2265
2
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
3
Cimetropium Experimental, Investigational Phase 4 150521-16-7
4 Pharmaceutical Solutions Phase 4
5 Cola Phase 4
6 Psychotropic Drugs Phase 4
7 Anti-Anxiety Agents Phase 4
8 GABA Modulators Phase 4
9 Anesthetics, General Phase 4
10 Hypnotics and Sedatives Phase 4
11 Anesthetics, Intravenous Phase 4
12 Calamus Phase 4
13
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
14
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
15
Rocuronium Approved Phase 3 119302-91-9, 143558-00-3 441290
16
tannic acid Approved Phase 3 1401-55-4
17
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
18
Ravulizumab Approved, Investigational Phase 3 1803171-55-2
19
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
20
Hydroxychloroquine Approved Phase 3 118-42-3 3652
21
Azithromycin Approved Phase 3 83905-01-5 447043 55185
22
Amifampridine Approved, Investigational Phase 3 54-96-6 5918
23
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
24
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
25
Nifedipine Approved Phase 3 21829-25-4 4485
26 Rozanolixizumab Investigational Phase 3 1584645-37-3
27 Immunoglobulin G Phase 3
28 Immunologic Factors Phase 2, Phase 3
29 Rho(D) Immune Globulin Phase 3
30 gamma-Globulins Phase 3
31 Vaccines Phase 3
32 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
33 Antineoplastic Agents, Immunological Phase 2, Phase 3
34 Neuromuscular Blocking Agents Phase 3
35 Anti-Infective Agents Phase 3
36 Anti-Bacterial Agents Phase 3
37 Adrenergic beta-Agonists Phase 2, Phase 3
38 Respiratory System Agents Phase 2, Phase 3
39 Anti-Asthmatic Agents Phase 2, Phase 3
40 Albuterol Phase 2, Phase 3
41 Adrenergic Agonists Phase 2, Phase 3
42 Bronchodilator Agents Phase 2, Phase 3
43 Antirheumatic Agents Phase 3
44 Complement System Proteins Phase 3
45 Antiparasitic Agents Phase 3
46 Antiprotozoal Agents Phase 3
47 Antimalarials Phase 3
48 Potassium Channel Blockers Phase 3
49 Cholinergic Agents Phase 3
50 abobotulinumtoxinA Phase 3

Interventional clinical trials:

(show top 50) (show all 144)
# Name Status NCT ID Phase Drugs
1 Usefulness Of Flospan As A Premedication For Colonoscopy : A Randomized Double Blind Controlled Trial Unknown status NCT01842932 Phase 4 Phloroglucin;Cimetropium bromide;Placebo
2 A Randomized Trial of Plasma Exchange vs. IVIG in the Treatment of Myasthenia Gravis Completed NCT01179893 Phase 4
3 Comparison of Two Tapering Strategies of Prednisone in Patients With Generalised Myasthenia Gravis Treated With Prednisone and Azathioprine: a Single-blind Randomised Controlled Multicenter Study Completed NCT00987116 Phase 4 Prednisone - Azathioprine
4 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
5 Changes of Skin Resistance After Midazolam and After the End of Anaesthesia Completed NCT03791424 Phase 4 Midazolam
6 Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis Recruiting NCT03510546 Phase 4 Pyridostigmine;Placebo oral capsule
7 A Pilot Trial To Assess The Feasibility And Efficacy Of Subcutaneous Immunoglobulin In Patients With Myasthenia Gravis Exacerbation Unknown status NCT02774239 Phase 3 Human normal immunoglobulin G (IgG)
8 A Trial of Mycophenolate Mofetil in Myasthenia Gravis Completed NCT00285350 Phase 3 mycophenolate mofetil
9 A Randomized, Controlled Clinical Study of GB-0998 for Treatment of Generalized Myasthenia Gravis Completed NCT00515450 Phase 3
10 FK506 Phase 3 Study: a Double Blind Placebo Controlled Study for Steroid Non-Resistant Myasthenia Gravis Patients Completed NCT00309088 Phase 3 tacrolimus;placebo
11 A Randomized, Double-blinded, Placebo-controlled, and Multi-centered Clinical Trial Evaluating the Efficacy and Safety of Tacrolimus Capsule in Myasthenia Gravis That Was Insufficiently Treated by Glucocorticoid Therapy Completed NCT01325571 Phase 3 Tacrolimus capsule;Placebo
12 FK506 Phase 3 Study: An Open Study for Steroid Resistant, Non-Thymectomized MG Patients Completed NCT00309101 Phase 3 tacrolimus
13 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG) Completed NCT01997229 Phase 3 Placebo
14 A Randomized, Double-Blind Study to Evaluate the Safety of Continued Treatment With CellCept in Patients With Well-Controlled Myasthenia Gravis Receiving a Stable Dose of Prednisone Completed NCT00408213 Phase 3 mycophenolate mofetil [CellCept];Placebo
15 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, 36-Week Trial to Assess the Efficacy and Safety of Adjunct Mycophenolate Mofetil (MMF) to Maintain or Improve Symptom Control With Reduced Corticosteroid in Subjects With Myasthenia Gravis Completed NCT00683969 Phase 3 mycophenolate mofetil (CellCept);placebo
16 IVIG Treatment Compared to Placebo in Patients With Myasthenia Gravis: A Randomized Clinical Trial Completed NCT00306033 Phase 3 Intravenous ImmuneGlobulin
17 A Phase III, Open-label Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG) Completed NCT02301624 Phase 3 Placebo
18 A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients Completed NCT03304054 Phase 3 Amifampridine Phosphate;Placebo Oral Tablet
19 A Multi-Center, Single-Blind, Randomized Study Comparing Thymectomy to No Thymectomy in Non-Thymomatous Myasthenia Gravis (MG) Patients Receiving Prednisone Completed NCT00294658 Phase 3 prednisone alone
20 A Multicenter, Prospective, Open-label, Non-controlled Clinical Trial to Assess the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients With Myasthenia Gravis Exacerbations Completed NCT02413580 Phase 3
21 Requirement of Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac Arrest - a Pilot Study Completed NCT01719770 Phase 3 rocuronium
22 Phase 3: Randomised Controlled Trial of Rituximab in Active Ulcerative Colitis Completed NCT00261118 Phase 2, Phase 3 Rituximab
23 An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients With Refractory Generalized Myasthenia Gravis Recruiting NCT03759366 Phase 3 Eculizumab
24 A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis Recruiting NCT04115293 Phase 3 zilucoplan (RA101495);Placebo
25 A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness Recruiting NCT03770403 Phase 3
26 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis Recruiting NCT03920293 Phase 3 Placebo
27 The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy Recruiting NCT01727193 Phase 3 Azathioprine;Leflunomide
28 Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis Recruiting NCT03914638 Phase 2, Phase 3 Salbutamol 4Mg Tablet;Placebo oral capsule
29 Postoperative Pain and Quality of Life for Patients Undergoing Mediastinal Tumor Resection by Subxiphoid and Intercostal VATS：A Randomized Controlled Trial Recruiting NCT03521986 Phase 3
30 Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial Recruiting NCT04339816 Phase 3 Azithromycin;Hydroxychloroquine;Placebo
31 Long Term Safety Study of Amifampridine Phosphate in Patients With MuSK Antibody Positive and AChR (Acetylcholine Receptor) Antibody Positive Myasthenia Gravis Active, not recruiting NCT03579966 Phase 3 Amifampridine Phosphate
32 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness Active, not recruiting NCT03669588 Phase 3
33 A Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Safety and Efficacy of Rituximab (Mabthera®) in Patients With New Onset Generalized Myasthenia Gravis (MG) Active, not recruiting NCT02950155 Phase 3 Rituximab;Sodium Chloride solution
34 A Randomized, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Enrolling by invitation NCT04124965 Phase 3 Rozanolixizumab
35 A 48-Week Prospective, Double-Blinded, Randomized, Cross-over Design in Multicenter Study of 250 Unit of Dysport Versus 50 Unit of Neuronox Injection For Cervical Dystonia in Thai Patients Enrolling by invitation NCT03805152 Phase 3 Neuronox(R);Dysport (R)
36 A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis Not yet recruiting NCT04225871 Phase 3 zilucoplan (RA101495)
37 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Suspended NCT03971422 Phase 3 Rozanolixizumab
38 Efficacy of Prednisone In the Treatment of Ocular Myasthenia: The EPITOME' Study Terminated NCT00995722 Phase 3 Prednisone;Placebo
39 Study of Different Doses of Nifedipine to Treat Preterm Labor Terminated NCT00137501 Phase 3 Nifedipine
40 A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Active Targeted Immunotherapy CV-MG01 in Patients With Moderate to Severe Myasthenia Gravis. Withdrawn NCT03165435 Phase 2, Phase 3
41 A Randomized, Double-blind, Placebo-Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness Completed NCT02965573 Phase 2 Placebo
42 A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Preliminarily Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of CFZ533 in Patients With Moderate to Severe Myasthenia Gravis Completed NCT02565576 Phase 2 Placebo;CFZ533
43 Phase II Trial of Methotrexate in Myasthenia Gravis Completed NCT00814138 Phase 2 Methotrexate
44 A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis Completed NCT03052751 Phase 2 UCB7665
45 A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis Completed NCT02473952 Phase 2 IGIV-C;Placebo
46 Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis Completed NCT02100969 Phase 2 HIZENTRA ®
47 B Cell Targeted Treatment In Myasthenia Gravis (BeatMG): A Phase II Trial of Rituximab In Myasthenia Gravis Completed NCT02110706 Phase 2 Rituximab;Placebo
48 A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis Completed NCT02473965 Phase 2 IGIV-C;Placebo
49 Phase 1-2 Pilot Study of Rituximab (Rituxan) in Refractory Myasthenia Gravis. Completed NCT00619671 Phase 1, Phase 2 Rituximab (Rituxan)
50 A First-in-human and Proof-of-concept Study to Assess the Safety, Tolerability and Immunogenic Response of CV-MG01, Acetylcholine Receptor Mimetic Peptides, as Potential Therapeutic Vaccine, in Patients With Myasthenia Gravis Completed NCT02609022 Phase 1, Phase 2

Search NIH Clinical Center for Myasthenia Gravis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cyclophosphamide
Cyclosporine
Neostigmine
Neostigmine bromide
Neostigmine Methylsulfate
Pyridostigmine
Pyridostigmine Bromide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myasthenia Gravis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myasthenia Gravis:
Hematopoietic stem cells for refractory myasthenia gravis
Embryonic/Adult Cultured Cells Related to Myasthenia Gravis:
Peripheral blood-derived hematopoietic stem cells

Cochrane evidence based reviews: myasthenia gravis

Sources

Genetic Tests for Myasthenia Gravis

About this section

Genetic tests related to Myasthenia Gravis:

# Genetic test Affiliating Genes
1 Myasthenia Gravis 29
Sources

Anatomical Context for Myasthenia Gravis

About this section

MalaCards organs/tissues related to Myasthenia Gravis:

40
Thymus, T Cells, Testes, Eye, B Cells, Skeletal Muscle, Thyroid
Sources

Publications for Myasthenia Gravis

About this section

Articles related to Myasthenia Gravis:

(show top 50) (show all 13948)
# Title Authors PMID Year
1
An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. 61 56
17687331 2007
2
Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. 56 61
15843529 2005
3
Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. 61 56
12417565 2002
4
Myasthenia gravis in a woman with congenital AChR deficiency due to epsilon-subunit mutations. 56 61
12034803 2002
5
The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children. 56 61
10711889 2000
6
Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. 56 61
10606626 1999
7
Immunogenetic heterogeneity and associated autoimmune disorders in myasthenia gravis: a population-based survey in the province of Ferrara, northern Italy. 56 61
7887131 1994
8
Familial autoimmune myasthenia gravis. 56 61
7908425 1994
9
Familial autoimmune myasthenia gravis with different pathogenetic antibodies. 61 56
3225607 1988
10
Myasthenia gravis in monozygotic twins. Clinical follow-up nine years after thymectomy. 56 61
6541031 1984
11
Heterozygous C2-deficiency and myasthenia gravis. 61 56
7191069 1980
12
Gm allotypes in myasthenia gravis. 61 56
6103092 1980
13
A genetic study of infantile and juvenile myasthenia gravis. 56 61
5026010 1972
14
Familial myasthenia gravis. Report of 27 patients in 12 families and review of 164 patients in 73 families. 61 56
5146412 1971
15
Genetic study of sample of 70 patients with myasthenia gravis. 61 56
4976972 1968
16
Familial myasthenia gravis. 61 56
6036434 1967
17
Myasthenia gravis occurring in families. 61 56
5948009 1966
18
MYASTHENIA GRAVIS IN TWO SIBLINGS. 56 61
14237778 1965
19
Unusual familial occurrence of myasthenia gravis. 56 61
13823698 1960
20
Acupuncture for ocular myasthenia gravis: A protocol for systematic review and meta-analysis. 42 61
32332667 2020
21
COVID-19 in Refractory Myasthenia Gravis- A Case Report of Successful Outcome. 61 42
32508329 2020
22
Clinical syndromes of myasthenia in infancy and childhood. A review. 56
341864 1978
23
Ptosis that resolves with application of an ice pack. 42
32299807 2020
24
The use of sugammadex in a patient with myasthenia gravis. 61 54
20105151 2010
25
Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for Myasthenia gravis implications. 61 54
20138518 2010
26
A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis. 54 61
19675582 2010
27
Structure-activity relationship of quaternary acetylcholinesterase inhibitors - outlook for early myasthenia gravis treatment. 54 61
20345342 2010
28
Myasthenia gravis patients with anti-MuSK antibodies. 61 54
20102061 2009
29
The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis. 54 61
19693092 2009
30
[Mediation of cellular immune response by TP5 in pathogenesis of myasthenia gravis]. 54 61
20193562 2009
31
Methylacridinium and its cholinergic properties. 54 61
19565307 2009
32
The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates. 54 61
19745065 2009
33
[Effects of acetylcholinesterase inhibitors on patients with MuSK antibody positive myasthenia gravis]. 61 54
19999149 2009
34
Immunocapture and identification of cell membrane protein antigenic targets of serum autoantibodies. 61 54
19332416 2009
35
Autoimmune disorders of the neuromuscular junction. 54 61
19428298 2009
36
Acetylcholinesterase inhibitors in MG: to be or not to be? 54 61
19260048 2009
37
Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status. 61 54
19587811 2009
38
Interleukin-10 promoter polymorphisms in myasthenia gravis. 54 61
19299022 2009
39
Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR. 54 61
19187062 2009
40
Muscle-specific receptor tyrosine kinase antibody-positive and seronegative myasthenia gravis. 61 54
19349708 2009
41
Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. 54 61
18728167 2008
42
A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. 54 61
18852352 2008
43
Hypothetical review: thymic aberrations and type-I interferons; attempts to deduce autoimmunizing mechanisms from unexpected clues in monogenic and paraneoplastic syndromes. 54 61
18727623 2008
44
Identification of CTLA-4 isoforms produced by alternative splicing and their association with myasthenia gravis. 54 61
18595775 2008
45
Acetylcholinesterase inhibitors and cholinergic modulation in Myasthenia Gravis and neuroinflammation. 61 54
18684515 2008
46
[Thymopentin 5 in treatment of relapse after extended thymectomy: a randomized comparative clinical trial of 135 patients with myasthenia gravis]. 54 61
19087694 2008
47
Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor. 61 54
18657424 2008
48
Muscle-specific kinase (MuSK) antibody-associated myasthenia gravis after bone marrow transplantation. 61 54
18537145 2008
49
Serum BAFF expression in patients with myasthenia gravis. 54 61
18586330 2008
50
PTPN22 R620W promotes production of anti-AChR autoantibodies and IL-2 in myasthenia gravis. 61 54
18533277 2008
Sources

Variations for Myasthenia Gravis

About this section
Sources

Expression for Myasthenia Gravis

About this section
Search GEO for disease gene expression data for Myasthenia Gravis.
Sources

Pathways for Myasthenia Gravis

About this section

Pathways related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Allograft rejection 1 36
Show member pathways
 12.76 TNFSF13B TNF IL4 IL2 IL10 IFNG
2
Immune response NFAT in immune response 22
Show member pathways
 12.59 TNF IL4 IL2 IL10 IFNG
3
Th17 cell differentiation 36
Show member pathways
 12.54 TNF IL4 IL2 IL10 IFNG
4
T cell receptor signaling pathway 36
Show member pathways
 12.54 TNF IL4 IL2 IL10 IFNG CTLA4
5
NF-kappaB Signaling 4
12.32 TNFSF13B TNF IL4 IL2 IL10 IFNG
6
Folate Metabolism 1
Show member pathways
 12.28 TNF IL4 IL2 IFNG
7
Toxoplasmosis 36
Show member pathways
 12.22 TNF IL4 IL10 IFNG
8
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.21 TNF IL4 IL2 IL10 IFNG
9
Hematopoietic Stem Cells and Lineage-specific Markers 64
11.9 TNF IL4 IL2 IL10 IFNG
10
IL27-mediated signaling events 1
Show member pathways
 11.88 TNF IL2 IL10 IFNG
11
Rheumatoid arthritis 36
11.82 TNFSF13B TNF IFNG CTLA4
12
Glucocorticoid receptor regulatory network 1
11.75 IL4 IL2 IFNG
13
Postsynaptic nicotinic acetylcholine receptors 65
Show member pathways
 11.74 CHRNG CHRNE CHRNA1
14
Dendritic Cells Developmental Lineage Pathway 64
11.71 TNF IL2 IL10 IFNG
15
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.62 TNF IL2 IFNG
16
Innate Lymphoid Cells Differentiation 64
11.62 TNF IL4 IL2 IL10 IFNG
17
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.6 TNF IL2 IFNG
18
Agrin Interactions at Neuromuscular Junction 63
11.55 RAPSN MUSK CHRNA1 AGRN
19
Photodynamic therapy-induced AP-1 survival signaling. 1
11.51 TNF IL2 IFNG
20
Spinal Cord Injury 1
11.51 TNFSF13B TNF MBP IL4 IL2 IFNG
21
Malaria 36
11.5 TNF IL10 IFNG
22
Interleukin-10 signaling 65
11.48 TNF IL4 IL10
23
Aryl Hydrocarbon Receptor Pathway 1
11.47 TNF IL2 IFNG
24
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.43 TNF IL4 IL2 IFNG CTLA4
25
Th2 Differentiation 64
11.42 IL4 IL2 IL10 IFNG
26
African trypanosomiasis 36
11.34 TNF IL10 IFNG
27
Inflammatory Response Pathway 1
11.27 IL4 IL2 IFNG
28
IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types 64
Show member pathways
 11.26 TNF IL2 IL10 IFNG
29
Development and heterogeneity of the ILC family 1
11.25 TNF IL4 IFNG
30
OX40 Pathway 63
11.08 IL4 IL2 IL10 IFNG
31
G-protein signaling_Rap2B regulation pathway 22
10.96 TNFSF13B TNF MUSK IL4 IL2 IL10
32
Succinylcholine Pathway, Pharmacokinetics/Pharmacodynamics 60
10.77 RYR1 CHRNE CHRNA1
33
Cytokines and Inflammatory Response 1
10.48 TNF IL4 IL2 IL10 IFNG
Sources

GO Terms for Myasthenia Gravis

About this section

Cellular components related to Myasthenia Gravis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.18 TNFSF13B TNF RYR1 RAPSN MUSK MBP
2 extracellular region GO:0005576 10.06 TTN TNFSF13B TNF IL4 IL2 IL10
3 cell junction GO:0030054 9.87 RAPSN MUSK CHRNG CHRNE CHRNA1 AGRN
4 postsynaptic membrane GO:0045211 9.65 RAPSN MUSK CHRNG CHRNE CHRNA1
5 synapse GO:0045202 9.56 RAPSN MUSK MBP CHRNG CHRNE CHRNA1
6 acetylcholine-gated channel complex GO:0005892 9.33 CHRNG CHRNE CHRNA1
7 neuromuscular junction GO:0031594 9.02 RAPSN MUSK CHRNE CHRNA1 ACHE

Biological processes related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.08 TTN TNF MUSK IL4 IFNG
2 positive regulation of protein phosphorylation GO:0001934 9.95 TNF MUSK IL2 IFNG
3 positive regulation of inflammatory response GO:0050729 9.87 TNF IL2 IFNG
4 chemical synaptic transmission GO:0007268 9.85 RAPSN MBP CHRNG CHRNE CHRNA1
5 excitatory postsynaptic potential GO:0060079 9.84 CHRNG CHRNE CHRNA1
6 positive regulation of T cell proliferation GO:0042102 9.83 TNFSF13B IL4 IL2
7 humoral immune response GO:0006959 9.83 TNF IFNG AIRE
8 regulation of postsynaptic membrane potential GO:0060078 9.82 CHRNG CHRNE CHRNA1
9 nervous system process GO:0050877 9.82 CHRNG CHRNE CHRNA1
10 muscle contraction GO:0006936 9.78 TTN RYR1 CHRNG CHRNE
11 positive regulation of interleukin-6 secretion GO:2000778 9.77 TNF MBP IFNG
12 response to nicotine GO:0035094 9.77 CHRNG CHRNE CHRNA1
13 positive regulation of B cell proliferation GO:0030890 9.74 TNFSF13B IL4 IL2
14 neuromuscular junction development GO:0007528 9.73 MUSK CHRNA1 AGRN
15 neuromuscular synaptic transmission GO:0007274 9.72 CHRNG CHRNE CHRNA1
16 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.69 TNF MBP
17 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.69 IL4 IL10
18 positive regulation of cytokine secretion GO:0050715 9.69 TNF IL10 IFNG
19 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.68 MBP IL10
20 negative regulation of amyloid-beta clearance GO:1900222 9.68 TNF IFNG
21 positive regulation of isotype switching to IgG isotypes GO:0048304 9.68 IL4 IL2
22 negative regulation of T-helper 17 cell differentiation GO:2000320 9.67 IL4 IL2
23 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.67 TNF IFNG
24 endothelial cell apoptotic process GO:0072577 9.67 TNF IL10
25 microglial cell activation GO:0001774 9.67 TNF IL4 IFNG
26 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.67 TNF IL4 IL2 IFNG
27 positive regulation of mononuclear cell migration GO:0071677 9.64 TNF IL4
28 type 2 immune response GO:0042092 9.63 IL4 IL10
29 negative regulation of cytokine production involved in immune response GO:0002719 9.63 TNF IL10
30 positive regulation of cellular respiration GO:1901857 9.62 IL4 IFNG
31 neuroinflammatory response GO:0150076 9.62 IL4 IFNG
32 regulation of synaptic growth at neuromuscular junction GO:0008582 9.61 MUSK AGRN
33 negative regulation of cytokine secretion involved in immune response GO:0002740 9.61 TNF IL10
34 regulation of isotype switching GO:0045191 9.58 IL4 IL10
35 B cell costimulation GO:0031296 9.58 TNFSF13B IL4
36 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.54 TNF IFNG
37 receptor biosynthetic process GO:0032800 9.52 TNF IL10
38 regulation of regulatory T cell differentiation GO:0045589 9.5 IL2 IFNG CTLA4
39 positive regulation of vitamin D biosynthetic process GO:0060557 9.43 TNF IFNG
40 positive regulation of chemokine biosynthetic process GO:0045080 9.43 TNF IL4 IFNG
41 positive regulation of nitrogen compound metabolic process GO:0051173 9.4 TNF IFNG
42 positive regulation of MHC class II biosynthetic process GO:0045348 9.33 IL4 IL10 IFNG
43 immune response GO:0006955 9.28 TNFSF13B TNF MBP IL4 IL2 IL10
44 synaptic transmission, cholinergic GO:0007271 9.26 RAPSN CHRNG CHRNE CHRNA1

Molecular functions related to Myasthenia Gravis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.36 TTN TNFSF13B TNF TMPO RYR1 RAPSN
2 calmodulin binding GO:0005516 9.76 TTN RYR1 MBP AKAP12
3 ion channel activity GO:0005216 9.73 RYR1 CHRNG CHRNE CHRNA1
4 neurotransmitter receptor activity GO:0030594 9.65 CHRNG CHRNE CHRNA1
5 protease binding GO:0002020 9.62 TTN TNF RYR1 MBP
6 extracellular ligand-gated ion channel activity GO:0005230 9.54 CHRNG CHRNE CHRNA1
7 acetylcholine-gated cation-selective channel activity GO:0022848 9.43 CHRNG CHRNE CHRNA1
8 cytokine activity GO:0005125 9.43 TNFSF13B TNF IL4 IL2 IL10 IFNG
9 acetylcholine receptor activity GO:0015464 9.33 CHRNG CHRNE CHRNA1
10 acetylcholine binding GO:0042166 8.92 CHRNG CHRNE CHRNA1 ACHE
Sources

Sources for Myasthenia Gravis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....